MicroRNAs (miRNAs) are endogenous non-coding RNAs that are known to be involved in the pathogenesis of tumors. Gastric carcinoma (GC) is a common malignancy worldwide. The aim of this study was the identification of the expression signature and functional roles of aberrant miRNAs in GC. Initial screening established a profile of aberrantly expressed miRNAs in tumors. miR-370 was confirmed to be overexpressed in GC tissues. Higher expression of miR-370 in GC tissues was associated with more advanced nodal metastasis and a higher clinical stage compared with controls. In addition, significantly higher level of miR-370 was noted in the plasma of GC patients compared with controls. Patients having more invasive or advanced tumors also exhibited a higher plasma level of miR-370. In vitro assays indicated that exogenous miR-370 expression enhanced the oncogenic potential of GC cells. The AGS-GFPM2 cells with exogenous miR-370 expression also exhibited enhanced abdominal metastatic dissemination in nude mice. Reporter assays confirmed that miR-370 targeted predicted sites in 3 0 UTR of transforming growth factor-b receptor II (TGFb-RII) gene. The exogenous miR-370 expression decreased TGFb-RII expression and the phosphorylation of Smad3 elicited by TGFb1. The TGFb1-mediated repression in cell migration was reverted by exogenous miR-370 expression. A reverse correlation between miR-370 and TGFb-RII expression was noted in GC tissues. This study concludes that miR-370 is a miRNA that is associated with GC progression by downregulating TGFb-RII. The miRNA expression profile described in this study should contribute to future studies on the role of miRNAs in GC.
Introduction
Gastric carcinoma (GC) is the second most common malignancy in the world (Wu et al., 2006; Lin et al., 2007; Lo et al., 2009) . It causes 12% of all cancer-related deaths and the toll is estimated to be one million deaths each year (Petrocca et al., 2008; Zhang et al., 2008) . Identification of the molecular alterations involved in the pathogenesis of GC may help with the developing diagnostic markers that aid therapeutic intervention (Motoyama et al., 2008; Lo et al., 2009) . MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of translation and in the degradation of target mRNAs (Dalmay and Edwards, 2006; Bartel, 2009 ). Since a miRNA is able to regulate hundreds of genes (Selbach et al., 2008) , it is thought that miRNAs may be involved in the regulation of expression of up to 30% of human genes (Petrocca et al., 2008) . Understanding the expression profile of miRNAs and the function of individual miRNAs will help with the validation of specific miRNA as crucial diagnostic markers and also provide therapeutic targets for cancer treatment.
Previous studies have suggested that miRNA have major functions during carcinogenesis and may act as either oncogenes or suppressors (Volinia et al., 2006) . For instance, miR-21 has been shown to be overexpressed in a variety of cancers and targets phosphatase and tensin homolog (PTEN), reversion-inducingcysteine-rich protein with kazal motifs (RECK), programmed cell death and four other genes as well as tropomyosin-1 (Meng et al., 2006; Si et al., 2007; Zhu et al., 2007; Lu et al., 2008; Zhang et al., 2008) . In contrast, let-7 is a tumor-suppressive miRNA family and is underexpressed in various tumors; it targets Ras, HMGA2 and others genes (Johnson et al., 2005; Yanaihara et al., 2006; Motoyama et al., 2008) . In previous studies, miR-21 and let-7 have been shown to be oncogenic and suppressive with respect to GC, respectively (Motoyama et al., 2008; Zhang et al., 2008) . A recent study also found overexpression of the miR-221 and miR-222 clusters in GC tissues and that these miRNAs target the Cip/Kip cell cycle regulators in GC cells (Kim et al., 2009) . Transforming growth factor-b (TGFb) has pluripotent roles in regulating biological and pathological processes (van den Brink and Offerhaus, 2007; Massague, 2008) . On ligand binding, the TGFb receptor II (TGFb-RII) activates TGFb-RI and transduces signals through a cascade of elements including Smad signaling molecules (Massague, 2008; Ehata et al., 2011) . SB431542 blocks Smad signaling by inactivating TGFb1-RI receptor kinase (Inman et al., 2002) . Impairment of TGFb signaling in GC models appeared to accelerate tumor growth (Komuro et al., 2009 ) and resistance to the TGFb suppressor seems to be an important event in gastric carcinogenesis (Ju et al., 2003) . A recent study has shown that E2F2 upregulates the expression of the miR-106b-25 polycistronic cluster, which targets TGFb signaling and enhances gastric carcinogenesis (Petrocca et al., 2008) . Further elucidation of the functional impacts of aberrant miRNA expression levels and identification of their targets that are involved in gastric pathogenesis will help with the development of miRNA-based therapies (Brown and Naldini, 2009) .
The differential expression profile of miRNAs during GC has been established (Volinia et al., 2006; Petrocca et al., 2008; Katada et al., 2009) . In this study, the signature of aberrant miRNAs expression in Taiwanese patients was established by screening and by analysis using bioinformatics. The relevance of overexpressed of miR-370 in terms of the clinical progression of GC was dissected. It was found that miR-370 expression increased the migration of GC cells by disrupting TGFb signaling. The miR-370 level in GC tissues and in patient's plasma could be potential biomarkers.
Results

Subjects and miRNA expression profile
After performing quantitative (q)PCR array analysis, miRNAs having concordance for the DDCt in terms of being 40 or o0 relative to corresponding paired noncancerous mucosa (NCM) across at least five of the eight GCs tested were included for further investigation. These consisted of 7 and 22 miRNAs that exhibited average DDCt of 40.5 and oÀ1.5, which were considered as overexpressed and underexpressed, respectively ( Figure 1a ). The highest overexpression values were found for miR-125b, miR-370, miR-189 and miR-187. The most conspicuous underexpression values were found for miR-148a, miR-27a, miR-181c and miR200c. Several miRNA families were altered in a concomitant manner, such as the clusters Let-7d/e/i, miR-26a/26b, miR-30d/e and miR-221/222. Generalized association plots analysis identified high correlation for expression between Let-7i and Let-7d, between miR-182 and miR-135b, between miR-221 and miR-222, between miR-199b and Let-7e, between miR-21, miR-30d and Figure 1 miRNA expression profile in GC. (a) Differentially expressed miRNAs with an average DDCt41 or o1.5 in tumor cells compared with normal tissue. The expression level was presented as mean±s.e. of the DDCt from eight GC tissues. Red, overexpression; green, underexpression. (b) Left, generalized association plot analysis, unsupervised hierarchical algorithm of miRNA expression of the analyzed patients. Right, association plot analysis using miRNA expression profile indicated an association of expression profile in several clusters of miRNA, which were marked in dark red. miR-370 in gastric cancers S-S Lo et al miR-30e, and between miR-181c and miR-370 (Figure 1b ). In addition, some of the GCs had very similar overall miRNA expression profiles.
miR-370 overexpression in GC
The expression of miR-370, miR-222, miR-200c, miR-181c, miR-27a and miR-148a were further analyzed in a total of 33 GC and NCM pairs from the group 1 patients (Table 1) to confirm the changes in expression level in the tumor tissue (Meng et al., 2006 (Meng et al., , 2008 Liu et al., 2007; Ladeiro et al., 2008; Lujambio et al., 2008) . miR-370 was found to be generally overexpressed in GC, with a mean DDCt of 1.45 (Figure 2a) . miR-200c, miR181c, miR-27a and miR-148a were validated as generally underexpressed in GC. These results for expression were consistent with the initial array screening. Specifically, miR-148a was highly underexpressed in GC, with a mean DDCt of À2.52 (Figure 2a) . A correlation between the expression levels of miR-370 and miR-181c was noted (g ¼ 0.46, P ¼ 0.02). Receiver operating characteristic analyses indicated that the ÀDCt of miR-370 had a prediction power of 0.70 when separating GC and NCM ( Figure 2b) ; the prediction power of ÀDCt of miR-148a was 0.76, however, the prediction power of ÀDCt of other miRNAs was much poorer. GC samples with more advanced nodal involvement (N2, N3) and at the most advanced clinical stage (stage IV) showed significantly higher miR-370 expression compared with other groups (Figure 2c ). ÀDCt of miR-370 had a prediction power around 0.70 when separating clinical stage. GC samples with the most advanced clinical stage also showed higher miR-222 expression compared with other counterparts (Supplementary Figure S1A) .
Plasma miR-370 as potential diagnostic marker of GC To examine the feasibility of using the level of miR-370 as a diagnostic marker, preoperative plasma samples from patients were collected from 40 group 2 patients and 12 healthy controls (Table 1 ). qPCR analysis indicated that GC patients had significantly higher ÀDCt values in plasma for miR-370 than the controls (Figure 2d) , with a prediction power of 0.79 to distinguish controls and GC patients (Figure 2e ). In Table 1 The clinical parameters of the subjects miR-370 in gastric cancers S-S Lo et al week to fourth week of xenografic growth. However, the difference was not statistically significant ( Figure 5b ). As AGS-GFPM2 cells already have high tumorigenic potential by means of in vivo selection (Lin et al., 2007) , it is possible that an increase in miR-370 expression is not sufficient to further enhance tumorigenesis. Although miR-370 expression increased the colony formation capability of AGS cells in vitro, it was unable to stably induce tumorigenecity of AGS cells in vivo (Supplementary Figure S2A) . Exogenous miR-370 expression was also unable to enhance the xenografic growth of SC-M1 cells (Supplementary Figure S2B) . The contribution of miR-370 expression to the tumorigenesis of GC cells could be limited.
Notwithstanding the above findings, AGS-GFPM2 cells with exogenous miR-370 expression exhibited a significant increase in the abdomen dissemination of fluorescent metastatic foci (Figure 5c ), namely an increase in about 4.2-fold compared with the control (Figure 5d ). However, exogenous miR-370 expression did not initiate the intra-abdominal metastasis of Kato III or AGS cells (Supplementary Figure S2C) . Thus, findings of miR-370 in enhancing the metastasis of AGS-GFPM2 cells in nude mice may substantiate the human clinical findings, which pinpointed a linkage between GC metastasis and higher miR-370 expression.
miR-370 targeted TGFb-RII in GC cells
TGFb-RII has been predicted as a potential target of miR-370 using the TargetScan in silico module (http://targetscan.org/) ( Figure 6A, left) . To prove the 
(E-H) Phenotypic assays of AGS cells (E, F) and AGS-GFPM2 cells (G, H)
, with exogenous miR-370 expression (E, G), and the knockdown of endogenous miR-370 expression (F, H). (a-c) in (E, G), growth, migration and anchorage-independent colony formation, respectively. Left of (F, H), growth; Right of (F, H), migration. Data shown in (B-D) were the means±s.e. from duplicate analysis. Data shown in (E-H) were the means±s.e. from more than triplicate analysis. ns, not significant; *Po0.05; **Po0.01; ***Po0.001. Mann-Whitney analysis or two-way analysis of variance analysis. GFP, green fluorescent protein.
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S-S Lo et al repression of TGFb-RII by miR-370 was occurring, a wild-type TGFb-RII reporter construct, Wt, was transfected to cells. Relative to the control, normalized bgalactosidase activity in Kato III-miR-370 cells containing the construct was repressed by about 34% relative to the control ( Figure 6A , right). The mutant reporter plasmids at predicted A site and B site, designated A Mut, B Mut and AB Mut (double mutations) were generated ( Figure 6A , left). In Kato III-miR-370 cells, A site mutation or B site mutation resulted in a partial reversion of the b-galactosidase activity. Mutation in both sites resulted in a complete reversion of bgalactosidase activity ( Figure 6A , right). The findings suggested that the binding of miR-370 to these sites in 3 0 UTR may repress TGFb-RII expression. Exogenous miR-370 expression resulted in the slight decrease in TGFb-RII mRNA expression for o10% in Kato III cells and AGS cells, and 22% in AGS-GFPM2 cells ( Figure 6B, left) . Exogenous miR-370 expression decreased the TGFb-RII protein expression more eminently by 46%, 35% and 54% in Kato III, AGS and AGS-GFPM2 cells, respectively ( Figure 6C ). Knockdown of miR-370 expression increased the TGFb-RII mRNA expression in AGS-GFPM2 cells and increased TGFb-RII protein expression for around 50% in AGS-GFPM2-miR-370 cells ( Figure 6C ). The interference of miR-370 on TGFb-RII may be in both mRNA degradation and protein translation. To examine if miR-370 expression could impair TGFb signaling, cells were treated with 10 ng/ml TGFb1 for 1 h. Drastic induction of Smad3 phosphorylation was shown in Kato III-GFP cells and AGS-GFPM2 cells, while it was attenuated in cells with exogenous miR-370 expression, suggesting that miR-370-mediated decrease in TGFb-RII expression could attenuate TGFb signal ( Figure 6D ). The induction of Smad3 phosphorylation modulated by miR-370 LNA was attenuated by 1 mM SB431542 ( Figure 6E ). miR-370-mediated GC cell migration was associated with TGFb signaling As miR-370 expression increased the growth of Kato III cells and AGS cells, 10 ng/ml TGFb1 and 1 mM SB431542 was used to identify if the cell viability was associated with TGFb pathway. The analysis showed that miR-370-mediated TGFb-RII targeting was not associated with the viability of AGS cells ( Figure 7A ), Kato III cells (Supplementary Figure S3A) or AGS-GFPM2 cells (Supplementary Figure S3B) . With TGFb1 treatment, the migration of AGS-GFP cells and AGS-miR-370 cells was decreased, while the migration of both cells increased with the treatment of SB431542. SB431542 treatment did not increase the migration of AGS-miR-370 cells because the TGFb receptor activity in the cells could have been repressed by miR-370 to a very low level ( Figure 7B ). Knockdown of endogenous miR-370 expression by miR-370 LNA decreased the migration of AGS-GFPM2 cells, which was reverted by SB431542 treatment ( Figure 7C ). The decreased migration was associated with an increased Smad3 phosphorylation ( Figure 6E ). Knockdown of TGFb-RII expression was carried out to specify the direct relevance between TGFb miR-370 in gastric cancers S-S Lo et al receptor activation and cell migration. Transfection of si-TGFb-RII decreased the TGFb-RII mRNA expression and protein expression, and the phosphorylation of Smad3 in AGS-GFPM2 cells (Figures 7Da and b) . TGFb1 treatment decreased the migration of AGS-GFPM2 cells, while the knockdown of TGFb-RII expression increased the migration of cells (Figure 7Dc ). The anchorage-independent colony formation of Kato III cells was decreased with SB431542 treatment, while this was reversed by miR-370 expression (Supplementary Figure S3C) . The colony formation of SC-M1 cells was not affected by SB431542 (Supplementary Figure S3D) .
miR-370 overexpression was correlated with TGFb-RII downregulation in GC tissues
Immunohistochemistry was performed on tissue pairs. The cytosolic TGFb-RII immunoreactivity was rather homogeneous in NCM and there were intensive immunoreactivity in gastric covering epithelial cells, glandular cells and some stromal cells (Figure 8Aa ). However, more than half of GC (57%; 12/21) had drastic decrease in TGFb-RII immunoreactivity being scored as 1 or 0 (Figures 8Ab-d) . qPCR analysis also revealed the downregulation of TGFb-RII mRNA in GC relative to paired NCM ( Figure 8B ), despite that the downregulation was rather mild, as the mean ÀDCt value in NCM was À4.1 and that in GC was À4.8. A reverse correlation across TGFb-RII immunoreactivity and miR-370 expression was found in tumors, as GC exhibiting miR-370 overexpression had TGFb-RII underexpression ( Figure 8C ). No correlation was found between TGFb-RII mRNA expression and miR-370 expression ( Figure 8D ). In tissues, miR-370 overexpression may impact more on TGFb-RII protein level than on mRNA level.
Additional results were in Supplementary data. 
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Discussion
This study provides a differential expression spectrum of conserved miRNA in a cohort of GC. As the qPCR analysis gave quantification of the mature miRNAs rather than their precursors, our analysis should have identified functional miRNAs that are important to gastric tumorigenesis. The involvement of Let-7, miR-21 and miR-221, and miR-222 and miR-148 in gastric carcinogenesis has been identified previously (Volinia et al., 2006; Motoyama et al., 2008; Zhang et al., 2008; Katada et al., 2009; Kim et al., 2009) . These miRNAs, because they were annotated in our analysis, substantiate the validity of our approach. Our screening indicated that there was high expression of miR-125b in GC, which is consistent with a previous study (Volinia et al., 2006) . However, miR-125b has been shown to target p53 and repress apoptosis (Le et al., 2009) , and also targeted ERBB2 and ERBB3 to repress oncogenicity (Scott et al., 2007) . The functional implications of miR-125b in GC tumorigenesis remained to be addressed. Our tissue analysis indicated underexpression of miR-27a in GC; this miRNA has been found oncogenic to GC cells by targeting prohibitin (Liu et al., 2009) . This contradiction requires further clarification. In the previously uncharacterized miRNAs subset of this study, such as miR-189 and miR-187, this study adds to the information available on the role of miRNAs in GC and provides candidates for further clinical stratification and for the identification of therapeutic applications of these miRNAs. We identified that there was overexpression of miR-370 in GC tumors, which is in agreement with the findings for myeloid leukemia (Dixon-McIver et al., 2008) and endometrial carcinosarcoma undergoing progression (Castilla et al., 2011) . Specifically, miR-370 expression was found to be significantly higher at later stages of tumor development or had undergone more extensive metastasis compared with counterparts; this finding could be used to develop a new progression marker. As very few studies have ever addressed the functional effects of miR-370, we have extended functional characterization to verify its roles in GC progression. Meng et al. (2008) have specified miR-370 as a methylation-dependent miRNA acting as a growth suppressor in cholagiocarcinoma cell lines. Interleukin-6 treatment downregulates miR-370 expression, while 5-aza-dC upregulates miR-370 expression. miR-370 was also found downregulated in bladder carcinoma (Yoshino et al., 2011) . These findings seem in conflict with the miR-370 in gastric cancers S-S Lo et al results of our study. Interestingly, miR-148a has been found to undergo specific DNA hypermethylationassociated silencing in hepatocellular carcinoma cells (Lujambio et al., 2008) . As miR-148a was found to be remarkably underexpressed in our and other GC subsets (Katada et al., 2009) , and there are clues supporting the occurrence of DNA methylation in GC (Ando et al., 2008) , a discrepancy in DNA methylation status is unlikely underlies the difference in miR-370 expression. It was found that miR-370 targets MAP3K8, which in turn inactivates p38MAPK for suppression of cholangiocarcinoma cells (Meng et al., 2008) . However, we found that miR-370 also targets TGFb-RII as part of the oncogenicity in GC cells. As a miRNA is able to target multiple targets (Selbach et al., 2008) and miR125b is known to target both p53 and ERBB2 (Scott et al., 2007; Le et al., 2009) , it is plausible that both events co-exist in cells. Although one event can dominate in one cell type, another can dominate in a different cell type or under different circumstances. As some GC exhibited low miR-370 expression, it is postulated that the fraction of GC having miR-370 expression lower than NCM may undergo via a p38MAPK oncogenic pathway in tumor tissues. In agreement with the GC tissue results, we were able to identify increased amounts of miR-370 in the plasma of GC patients, the source of which might be primary tumors, which also supports the pathogenic involvement of miR-370 in gastric tumorigenesis.
The measurement of tumor-derived molecules in patient's plasma could be an important strategy that allows blood-based rapid detection of various cancers. It has been proposed that the plasma levels of miRNAs should be used as screening markers for lung and colorectal carcinomas (Hayashita et al., 2005; miR-370 in gastric cancers S-S Lo et al the basis of the frequent high levels of miR-370 expression in GC tissue, this study is the first attempt to detect plasma miR-370 in GC patients and to explore whether this miRNA might be able to act as a noninvasive marker. In agreement with the tissue studies, plasma miR-370 was also found to have a profound power when predicting GC and when evaluating GC progression. As plasma miR-370 in early tumors has been found to be significantly higher than controls even at such an early stage, this suggests that this assay has potential as a method of detecting early neoplasms.
Other than GC, overexpression of miR-370 was has only been reported in endometrial carcinosarcoma (Castilla et al., 2011) , a female solid tumor, thus it might be possible to validate the level of plasma miR-370 as a marker able to specifically distinguish GC from other carcinoma and help with the selection of male individuals for targeted therapy (Brown and Naldini, 2009) . A previous study has identified that upregulation of the miR-106b/miR-93/miR-25 cluster impairs G 1 /S arrest and apoptosis in GC cells and that this is associated with TGFb signaling (Petrocca et al., 2008) . Disruption in TGFb signaling facilitates the growth of diffuse-type GC (Komuro et al., 2009) . Furthermore, TGFb suppresses the progression of diffuse-type GC by inducing the differentiation of cancer-initiating cell sub-population (Ehata et al., 2011) . This study provided another line of evidence delineating the downregulation of TGFb-RII by miR-370 targeting in GC cells; interestingly, this was found to be associated with an increased GC cell mobility through modulation of TGFb signal. Although miR-370 expression also increased the growth and colony formation of GC cells, our analysis have excluded the influence of TGFb pathway on modulating miR-370-mediated tumor cell growth. However, since long-term TGFbRII blockage seemed to impair the colony formation capability of Kato III cells but not SC-M1 cells, TGFb pathway may mediate complicated regulation on GC pathogenesis, and different GC cell lines could have different degrees of dependence on TGFb pathway. Targeting of other genes associated with cell proliferation by miR-370 could also be the possible mechanism for growth regulation. This study concluded that miR-370 functions to modulate GC cell migration by regulating TGFb pathway. Such implications correlated with the clinical findings of high miR-370 expression in most advanced GCs.
Although miR-370 expression was sufficient to induce GC in vitro oncogenic potential, it was not sufficient to initiate or enhance the in vivo tumorigenecity of GC cells. The potential impacts of miR-370 expression on apoptosis, differentiation, drug resistance and survival in hypoxia situation require further elucidation (Petrocca et al., 2008; Komuro et al., 2009; Ehata et al., 2011) . The role of TGFb pathway in xenografic tumor growth also needs clarification. Enhancement of intra-abdominal dissemination of AGS-GFPM2 GC cell sub-line by miR-370 expression being found in this study seems crucial for the test of therapeutic regimens as carcinomatosis is one the most serious causes underlying the mortality of GC patients (Lo et al., 2009) . We have shown that miR-370 is involved in the progression of GC and might be useful as a marker for diagnosis of GC, especially for those having more diffused spreading. Further insights into the functional and clinical implications of miR-370 and the uncharacterized miRNAs may contribute to the early diagnosis of GC and help with GC treatment.
Materials and methods
GC tissues and plasma samples
Resected tissues from 33 GC patients along with paired NCM from the group 1 (Table 1) patients were harvested at surgery. These patients received their operations during 2007 and 2008. None of the patients had received adjuvant chemotherapies before surgery. Eight tumor tissues evaluated to have 480% of their area occupied by tumor cells by microscopic examination and these were used to screen for aberrant miRNAs using a qPCR array. The results of this assay allowed the selection of the particular miRNAs that would be then further investigated.
Samples of the patients' blood were collected in the week before their operation from another group of 40 patients that received their operations during 2008 (group 2 in Table 1 ). Twelve healthy subjects served as controls for this part of the study. Each sample from these subjects consisted of 5 ml of whole blood collected in a heparin-coated tube. This study was approved by an institute review board and the subjects provided written informed consent before sampling.
Quantitative PCR Total RNA was purified by acid-phenol/chloroform extraction (Ambion, Austin, TX, USA). A mirVana PARIS Kit (Ambion) was used to isolate miRNA from the total RNA. Total RNA from the plasma samples and the miRNA from tissues, respectively, were used as inputs to the miRNA expression assay. A TaqMan MicroRNA Assays kit (Applied Biosystems, Foster City, CA, USA) was used to quantify the expression of mature miRNAs using a qPCR array containing 154 conserved miRNAs. The qPCR reactions were carried out using the Quantica real-time nucleic acid detection system (Techne Inc., Burlington, NJ, USA). TaqMan MicroRNA Assays supplies (Applied Biosystems) were also used to confirm the expression of miRNA in tissues. RNU19 or RNU6B was used as controls for tissue and cell analysis (Chen and Stallings, 2007; Liu et al., 2010) . miR-16 was used as a control for the plasma analysis (Ng et al., 2009) . mRNA expression of TGFb-RII and glyceraldehyde 3-phosphate dehydrogenase (internal control) was also analyzed using TaqMan qPCR system (Applied Biosystems). The mean threshold cycle (DCt) was achieved by normalization of the tested miRNA or mRNA against an internal control. The DDCt was used to measure relative changes in expression between tumor and NCM tissue or between experimental settings (Liu et al., 2010) . A negative control without a template was run in parallel to assess the overall specificity of the reaction. The 2 DDCt value represents the fold change in miRNA or mRNA expression.
Cell culture
The GC cell lines Kato III, AGS, AGS-GFPM2 and SC-M1 as well as 293FT cells, were cultured as previously described (Lin et 
